Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of parkinson disease

24Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Intrastriatal transplantation of gelatin microcarrier-attached human retinal pigment epithelial cells (hRPE-GM) may represent an alternative source for cell therapy in Parkinson disease (PD). The use of human retinal pigment epithelial (hRPE) cells in PD relies on the capacity of these cells to produce l-dopa as an intermediate product in the eumelanin synthesis pathway. We investigated the behavioral effects of hRPE-GM implants on forelimb use asymmetries and hindlimb motor deficits in unilateral and bilateral 6-hydroxydopamine (6-OHDA) rat models of PD. We report that intrastriatal unilateral implantation of hRPE-GM in rats with 6-OHDA nigrostriatal lesions produce an amelioration of the contralateral forelimb disuse and the contralateral hindlimb deficits. These results further support the possibility that implantation of cultured hRPE cells may be a promising therapeutic option for patients with PD. © 2007 American Association of Neuropathologists, Inc.

Cite

CITATION STYLE

APA

Cepeda, I. L., Flores, J., Cornfeldt, M. L., O’Kusky, J. R., & Doudet, D. J. (2007). Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of parkinson disease. Journal of Neuropathology and Experimental Neurology, 66(7), 576–584. https://doi.org/10.1097/nen.0b013e318093e521

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free